by medical devices and, by extension, drug-device combinations.

Article 117 specifically states that when a medicinal product is incorporated into a medical device, the entire product must comply with relevant provisions of the MDR. This mandates the involvement of a Notified Body to assess conformity and ensure compliance with the EU legislation.

Prior to initiating product development, developers should also engage with regulatory consultants who specialize in EU MDR consulting services. These experts can provide insights into the technical and operational aspects of compliance, as well as assist in identifying a suitable Notified Body that aligns with the type of product being developed.

Step 2: Selecting an Appropriate Notified Body

Choosing the right Notified Body is essential for compliance with the EU MDR. The choice influences the timelines, costs, and ultimately, the success of the product in the competitive market. Notified Bodies are designated organizations that provide third-party conformity assessment services. They are responsible for evaluating whether the requirements of the EU MDR have been met.

To select the most appropriate Notified Body for your drug-device combination, consider the following criteria:

• Scope of Designation: Ensure that the Notified Body is designated for the product class of your combination product.
• Expertise and Experience: Review the Notified Body’s expertise in drug-device combinations and their history of involvement with similar products.
• Communication and Responsiveness: Establish the responsiveness of the Notified Body during initial discussions. This factor is crucial for timely feedback and guidance throughout the project.
• Adequate Resources: Confirm that the selected Notified Body has sufficient resources and personnel to conduct the conformity assessment efficiently.

Once you’ve evaluated these criteria, perform due diligence by checking the Notified Body’s status and scope of activities. Comprehensive information about their designation can be found on official websites such as the EC Medical Device sector page.

Step 3: Preparing the Technical Documentation

Once a Notified Body has been selected, the next step involves preparing the technical documentation that demonstrates compliance with EU MDR requirements. This documentation serves as the foundation for the conformity assessment process and typically includes the following components:

• Product Description: Provide a detailed description of the drug-device combination, including indications, intended use, and key components.
• Evidence of Compliance with GSPR: Prepare a comprehensive plan outlining how each of the General Safety and Performance Requirements will be met. This plan should include risk management evaluations, clinical data, and preclinical studies.
• Labeling and Package Information: Create labeling that is compliant with regulatory requirements. Ensure that it provides accurate information about the product’s use.
• Manufacturing Process: Detail the manufacturing processes used, including compliance with good manufacturing practices (GMP). This section should demonstrate reproducibility of the product.
• Clinical Evaluation: Conduct a clinical evaluation in line with ICH-GCP guidelines to substantiate the product’s safety and efficacy. Prepare the Clinical Evaluation Report (CER) that aligns with the rigorous requirements for drug-device combinations.
• Post-Market Surveillance (PMS) Plan: Draft a PMS plan that outlines how ongoing safety and performance will be monitored once the product is on the market.

The technical documentation should be prepared following the structure indicated in the MDR and should be sufficiently comprehensive to satisfy the Notified Body’s requirements during the assessment process.

Step 4: Submission of Technical Documentation to Notified Body

Upon completion of the technical documentation, the next step is to formally submit this documentation to the selected Notified Body. This submission initiates the conformity assessment process, where the Notified Body will evaluate whether the product meets the requirements of the EU MDR.

During the submission process, ensure that you:

• Include a Cover Letter: Write a cover letter that outlines the purpose of the submission, specifying the product, the type of assessment requested, and any key details that the Notified Body should be aware of.
• Organize Documentation Clearly: Structure the submission with a clear table of contents and ensure that all documents are labeled consistently. This facilitates easier navigation during the review process.
• Maintain Transparency: Be open about any uncertainties or areas where there may be additional data or information required. This can often help streamline the review.

It is advisable to maintain regular communication with the Notified Body during the assessment phase. Establish points of contact and define timelines for feedback to ensure any issues can be addressed promptly.

Step 5: Engaging in Conformity Assessment and Addressing Queries

The Notified Body will start the conformity assessment once the documentation is submitted. Assessors will review the technical documentation and may request further information or clarification on specific topics. This phase can sometimes take several months, depending on the complexity of the drug-device combination.

During this period, it is essential to remain responsive to any queries raised by the Notified Body. Addressing these queries expediently not only expedites the review process but significantly mitigates the risk of delays in obtaining CE marking.

Common areas where further clarification might be requested include:

• Clinical Evidence: The Notified Body may necessitate additional clinical data to support claims regarding safety and efficacy, especially if the product involves innovative technologies or therapeutic modalities.
• Risk Management Procedures: Reviewers may require more detailed explanations of how risks are managed throughout the product lifecycle, demanding transparency about identified risks and mitigation strategies.
• Manufacturing and Process Controls: Additional information regarding adherence to manufacturing standards and controls might be sought, ensuring compliance with quality assurance principles.

Once the Notified Body completes its assessment and any outstanding queries are resolved, a recommendation for CE marking can ensue, significantly enhancing the product’s marketability within the EU.

Step 6: Post-Assessment and Regulatory Compliance Obligations

Following the successful completion of the conformity assessment and subsequent receipt of the CE mark, the responsibilities towards maintaining compliance continue. Post-market requirements are outlined in the EU MDR and include monitoring product performance and complying with regulatory reporting obligations.

Key post-approval commitments include:

• Post-Market Surveillance (PMS): Implement the PMS plan developed during the technical documentation phase. This plan should be continually updated to reflect real-world data and experience gathered from product usage.
• Periodic Safety Update Reports (PSUR): Prepare and submit PSURs at designated intervals to review the long-term safety and efficacy of the drug-device combination.
• Reporting Adverse Events: Establish a robust framework for reporting any adverse events associated with the product to the Notified Body and relevant regulatory authorities.
• Changes and Variations Management: If any changes are made to the product, a comprehensive assessment will be required to determine if re-evaluation by the Notified Body is necessary.

To align effectively with these obligations, it may be beneficial for organizations to integrate a dedicated compliance management system, facilitating continuous monitoring of regulatory activities and requirements.

Conclusion

Successfully navigating the regulatory pathway for drug-device combinations under the EU MDR requires meticulous planning, thorough understanding of compliance requirements, and active engagement with Notified Bodies. By following the sequential steps outlined in this guide, stakeholders can enhance their preparedness for regulatory scrutiny, ensuring their products meet the necessary standards for safety and efficacy within the European market.

Engaging EU MDR consulting services can provide further assistance in overcoming the complexities of this regulatory landscape. By leveraging expertise and guidance, organizations can streamline their path to market, thus improving their commercial prospects in the evolving field of drug-device combinations.